The cyclin D‐CDK4/6 complex is often hyperactivated in various tumours (e.g. NSCLC, head and neck, renal cell, breast, pancreatic and colorectal cancers), partly by gene amplification, and is therefore an attractive therapeutic target.33, 34. Here, CDK4 is linked to neoplasm.